Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Thomas B Borchardt

Ahmad Y Sheikh

Ayman Allian

Fredrik Lars Nordstrom

Michael J Rozema

Rodger F Henry

Geoff G Zhang

Peter T Mayer

Shuang Chen

Jayanthy Jayanth

Patrick J Marroum

Mathew M Mulhern

Madhup K Dhaon

Michael Rasmussen

Robert M Leanna

Lakshmi Bhagavatula

Larry Bartelt

Shekhar Viswanath

Geoff G Z Zhang

Ahmed A Othman

Mohamed-Eslam F Mohamed

Ben Klünder

Nathaniel Catron

Paul J Brackemeyer

Rolf Wagner

John T Randolph

Todd Warren Rockway

Dachun Liu

David A Betebenner

Douglas K Hutchinson

Allan C Krueger

Larry L Klein

Kent D Stewart

Ming Clinton Yeung

Charles A Flentge

Keith F McDaniel

M Robert Leanna

Russell Drew Cink

Darold L Madigan

Vincent S Stoll

Peggy Huang

Brian E Green

Mira Hinman

Teresa A Rosenberg

Richard D Bishop

Bradley D Gates

Daniel P Larson

Todd D Bosse

Alexander F Chu-Kung

John R Bellettini

Steven J Wittenberger

Seble H Wagaw

Xiaochun Lou

Albert Wayne Kruger

Kenneth M Engstrom

Michael G Fickes

Jorge Gandarilla

Matthew M Ravn

Deliang Zhou

Shailendra V Bordawekar

Ayman D Allian

Shailendra V Bordawar

Alexander Chu-Kung

Ben Kluender

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-&#x3b1;]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluorethyl)pyrrolidine-1-carboxamide and solid state forms thereof

A process for making (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile and salts thereof, and intermediates used in the process are disclosed.

Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile

N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.

Crystalline chemotherapeutic

ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ABT-263 crystalline forms

ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Salt of ABT-263 and solid-state forms thereof

A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.

Methods of manufacturing crystalline forms of rapamycin analogs

Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof: 

Crystalline forms of rapamycin analogs

Growing community of inventors

Kenosha, WI, United States of America

Thomas B Borchardt